StockIQpro
NASDAQ:CTSO

Cytosorbents Corp

Track all markets on TradingView
Track all markets on TradingView

Cytosorbents Corp's revenue grew 4.1% in fiscal 2025 to $37.1M while operating margin rose to −39.8%. Free cash flow was −$12.5M, −33.8% of revenue, and the diluted share count rose 14.3%.Summary generated from Cytosorbents Corp's SEC filings. Latest annual report filed Mar 30, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$37.1M
Revenue growth+4.1%
Revenue, 5-yr CAGR−2.0%
Gross margin71.5%
Operating margin−39.8%
Net margin−22.1%
ROIC−61.1%
Return on equity−96.4%
Debt / equity2.82
Free cash flow−$12.5M
FCF margin−33.8%
Share count change+14.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue4335313637
Operating income−23−32−32−16−15
Net income−25−33−29−21−8
Free cash flow−18−34−22−15−13

Recent filings

From SEC EDGAR

Peers

Surgical & medical instruments & apparatus